ParambirSinghDulaiMD

PubMed

• Tissue-specific reprogramming leads to angiogenic neutrophil specialization and tumor vascularization in colorectal cancer.
  Triet M Bui, Lenore K Yalom, Edward Ning, Jessica M Urbanczyk, Xingsheng Ren, Caroline J Herrnreiter, Jackson A Disario, Brian Wray, Matthew J Schipma, Yuri S Velichko...> ;The Journal of Clinical Investigation. 2024 Apr 1
• Defining Endoscopic Remission in Crohn's Disease: MM-SES-CD and SES-CD Thresholds Associated With Low Risk of Disease Progression.
  Neeraj Narula, Emily C L Wong, Parambir S Dulai, Jaiminkumar Patel, John K Marshall, Clara Yzet, Vipul Jairath, Ryan Ungaro, Jean-Frederic Colombel, Walter Reinisch> ;Clinical Gastroenterology and Hepatology. 2024 Feb 28
• Crohn's Patient Serum Proteomics Reveals Response Signature for Infliximab but not Vedolizumab.
  Carlos G Gonzalez, Toer W Stevens, Bram Verstockt, David J Gonzalez, Geert D'Haens, Parambir S Dulai> ;Inflammatory Bowel Diseases. 2024 Feb 17
• Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Naïve Crohn's Disease.
  Narula, N., Wong, E., Marshall, J., Jairath, V., Reinisch, W., Dulai, P.> ;The American Journal of Gastroenterology. 2024 Feb 9
• Pangenome comparison ofgenomospecies unveil genetic diversity and ecological insights.
  Oles, R., Terrazas, M., Loomis, L., Hsu, C., Tribelhorn, C., Ferre, P., Ea, A., Bryant, M., Carrow, H., Pride, D., Knight, R., Chu, H., Young, J., Sandborn, W., Dulai,...> ;Biorxiv. 2023 Dec 21
• Integrating Evidence to Guide Use of Biologics and Small Molecules for Inflammatory Bowel Diseases.
  Parambir S Dulai, Siddharth Singh, Vipul Jairath, Emily Wong, Neeraj Narula> ;Gastroenterology. 2024 Mar 1
• 3 citations
  Trends of inflammatory bowel disease from the Global Burden of Disease Study (1990-2019).
  Khushdeep Dharni, Arshdeep Singh, Sonika Sharma, Vandana Midha, Kirandeep Kaur, Ramit Mahajan, Parambir S Dulai, Ajit Sood> ;Indian Journal of Gastroenterology. 2024 Feb 1
• The importance of predicting patient responses to monoclonal antibodies for Crohn's disease.
  Nisha Ganesh, Stephen B Hanauer, Parambir S Dulai> ;Expert Opinion on Biological Therapy. 2023 Aug 30
• 1 citations
  Delayed Ustekinumab Responders in Ulcerative Colitis Have Greater Inflammatory Burden but Similar Outcomes as Early Responders.
  Emily C L Wong, Parambir S Dulai, John K Marshall, Vipul Jairath, Walter Reinisch, Neeraj Narula> ;Clinical Gastroenterology and Hepatology. 2023 Dec 1
• 3 citations
  Efficacy of biologic and small molecule agents as second-line therapy after exposure to TNF inhibitors in patients with ulcerative colitis: A propensity-matched cohort...
  Gursimran S Kochhar, Aakash Desai, Francis A Farraye, Raymond K Cross, Sandra El-Hachem, Parambir S Dulai, Miguel Regueiro> ;Alimentary Pharmacology & Therapeutics. 2023 Aug 1
• Correlations Between Gastrointestinal Symptoms and Endoscopic-Histologic Disease Activity in Adults with Ulcerative Colitis.
  Chung Sang Tse, Hang P Nguyen, Siddharth Singh, Parambir S Dulai, Jennifer Neill, Helen Le, Thierry Dervieux, Angelina E Collins, Brigid Sweeney Boland, Mark Valasek> ;Digestive Diseases and Sciences. 2023 Aug 1
• 4 citations
  Macrophage-endothelial cell crosstalk orchestrates neutrophil recruitment in inflamed mucosa.
  Xingsheng Ren, Laura D Manzanares, Enzo B Piccolo, Jessica M Urbanczyk, David P Sullivan, Lenore K Yalom, Triet M Bui, Connor Lantz, Hinda Najem, Parambir S Dulai, Amy...> ;The Journal of Clinical Investigation. 2023 Aug 1
• Role of hyperbaric oxygen therapy in patients with inflammatory bowel disease.
  Harpreet Kaur, Gursimran Singh Kochhar, Parambir S Dulai> ;Current Opinion in Gastroenterology. 2023 Jul 1
• 3 citations
  Safety and Effectiveness of Vedolizumab in Elderly Patients with Inflammatory Bowel Disease: A Systematic Review & Meta-Analysis.
  Saurabh Chandan, Jay Bapaye, Babu P Mohan, Daryl Ramai, Lena L Kassab, Ojasvini C Chandan, Parambir S Dulai, Gursimran S Kochhar, Dushyant Singh Dahiya> ;Journal of Clinical Gastroenterology. 2024 Apr 1
• Comparative Efficacy of Infliximab Versus Tofacitinib for Inducing Remission in Biologic Naive Ulcerative Colitis: A Propensity Matched Study.
  Emily C L Wong, Shahin Merat, Cristina Monaco, Parambir S Dulai, Vipul Jairath, John K Marshall, Walter Reinisch, Neeraj Narula> ;Digestive Diseases and Sciences. 2023 Jun 1
• 1 citations
  Predicting Endoscopic Improvement in Ulcerative Colitis Using the Ulcerative Colitis Severity Index.
  Emily C L Wong, Parambir S Dulai, John K Marshall, Vipul Jairath, Walter Reinisch, Neeraj Narula> ;Inflammatory Bowel Diseases. 2024 Mar 1
• Matching-adjusted Indirect Comparisons vs Propensity Score Matching with Individual Patient-level Data to Estimate Treatment Efficacy.
  Emily C L Wong, Parambir S Dulai, John K Marshall, Vipul Jairath, Walter Reinisch, Neeraj Narula> ;Inflammatory Bowel Diseases. 2024 Feb 1
• Combined Histological and Endoscopic Endpoints at Post-induction Lack Additional Prognostic Value Compared with Endoscopic Improvement Alone in Ulcerative Colitis: A P...
  Emily C L Wong, Parambir S Dulai, Badar Hasan, John K Marshall, Walter Reinisch, Neeraj Narula> ;Journal of Crohn's & Colitis. 2023 Jul 5
• 2 citations
  Vedolizumab and Adalimumab in Biologic-Naïve Ulcerative Colitis: Comparison of Patient-Level Clinical Trial Data and VARSITY for Week 6 Clinical Remission.
  Emily C L Wong, Parambir S Dulai, John K Marshall, Vipul Jairath, Walter Reinisch, Neeraj Narula> ;Digestive Diseases and Sciences. 2023 Jun 1
• 10 citations
  Stool multi-omics for the study of host-microbe interactions in inflammatory bowel disease.
  Consuelo Sauceda, Charlie Bayne, Khadijeh Sudqi, Antonio Gonzalez, Parambir S Dulai, Rob Knight, David J Gonzalez, Carlos G Gonzalez> ;Gut Microbes. 2022 Dec 12
• 25 citations
  Enhancing untargeted metabolomics using metadata-based source annotation.
  Gauglitz, J., West, K., Bittremieux, W., Williams, C., Weldon, K., Panitchpakdi, M., Di Ottavio, F., Aceves, C., Brown, E., Sikora, N., Jarmusch, A., Martino, C., Trip...> ;Nature Biotechnology. 2022 Dec 1
• 1 citations
  Predictors of Clinical Remission to Placebo in Clinical Trials of Crohn's Disease.
  Emily C L Wong, Parambir S Dulai, John K Marshall, Vipul Jairath, Walter Reinisch, Neeraj Narula> ;Inflammatory Bowel Diseases. 2023 Sep 1
• 7 citations
  Comparative Safety and Effectiveness of Biologic Therapy for Crohn's Disease: A CA-IBD Cohort Study.
  Siddharth Singh, Jihoon Kim, Jiyu Luo, Paulina Paul, Vivek Rudrapatna, Sunhee Park, Kai Zheng, Gaurav Syal, Christina Ha, Phillip Fleshner, Dermot McGovern, Jenny S Sa...> ;Clinical Gastroenterology and Hepatology. 2023 Aug 1
• Using a Clinical Decision Support Tool for Inflammatory Bowel Disease.
  Parambir S Dulai> ;Gastroenterology & Hepatology. 2022 Nov 1
• Baseline Patient-reported Symptoms Less Predictive Than MM-SES-CD for Endoscopic Remission in Crohn's Disease.
  Emily C L Wong, Achuthan Aruljothy, Parambir S Dulai, Jean-Frederic Colombel, John K Marshall, Marc Ferrante, Walter Reinisch, Neeraj Narula> ;Journal of Clinical Gastroenterology. 2023 Oct 1
• Join now to see all

Journal Articles

• Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium  
  Leah Katta, Robert Hirten, Shannon Chang, Dana Lukin, Edward V Loftus, David Faleck, Arun Swaminath, William J Sandborn, Sashidhar Varma Sagi, Sunanda Kane, Prianka Ch..., Nature
• Comparison of Multiplex Gastrointestinal Pathogen Panel and Conventional Stool Testing for Evaluation of Diarrhea in Patients with Inflammatory Bowel Diseases  
  Waseem Ahmad, Daniel Bouland, Nghia H Nguyen, David T Pride, Siddharth Singh, Parambir S Dulai, William J Sandborn, Brigid S Boland, Digestive Diseases and Sciences
• Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts  
  Parambir S Dulai, William J Sandborn, Brigid S Boland, Derek R Patel, Inflammatory Bowel Diseases
• Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium  
  Gursimran Kochhar, Justin Hartke, Sashidhar Varma Sagi, Edward V Loftus, Joseph Meserve, Robert Hirten, David Faleck, Shannon Chang, Dana Lukin, Farhad Peerani, Leah K..., Nature
• No Benefit of Concomitant 5-Aminosalicylates in Patients with Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data from Cli...  
  Siddharth Singh, Parambir S Dulai, William J Sandborn, Nature
• Join now to see all